Autologous Adipose Derived MSC (HB-adMSC) for Sub-Acute and Chronic Neurological Injury
Status:
Not yet recruiting
Trial end date:
2020-08-29
Target enrollment:
Participant gender:
Summary
This study aims to determine the safety of HB-adMSC infusion and treatment effects of
HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and
neuroinflammation after subacute and chronic neurological injury in adults.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hope Biosciences
Collaborator:
The University of Texas Health Science Center, Houston